Semaglutide Pre-filled Syringes Recalled for Sterility Assurance Issues
Thrive Health Solutions is recalling Semaglutide 2.5 mg/mL pre-filled syringes nationwide for lack of assurance of sterility. Patients with affected syringes should contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall involves an injectable pharmaceutical where sterility is critical. Although no illnesses or injuries have been reported, the lack of sterility assurance represents a risk-of-harm product, meeting the criteria for High severity.
Plain-English summary
Thrive Health Solutions, based in Englewood, Colorado, is recalling Semaglutide 2.5 mg/mL pre-filled syringes due to lack of assurance of sterility. The recalled product includes lot #H270221, which expires 12/26/2025.
The recall was issued because the manufacturer could not assure the sterility of the pre-filled syringes. Sterility is critical for injectable medications.
The product was distributed nationwide in the United States. Patients who have syringes from the affected lot should contact their healthcare provider immediately.
The recalled product
- Product
- Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112
- Manufacturer
- Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)
- Category
- Drug — Injectable medication
- Hazard
- lack-of-sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: H270221
- Exp 12/26/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27